Tumor genetically-engineered vaccine utilizing mucin-1 and survivin as target sites

Abstract

The invention relates to fields of tumor DNA vaccines, viral vector vaccines and protein vaccines and especially relates to a tumor genetically-engineered vaccine utilizing mucin-1 and survivin as target sites. The tumor genetically-engineered vaccine comprises recombinant DNA vectors of CpVR-MS and CpDV-IL2-MS. The invention also relates to a use of recombinant protein vaccines of S8 and 9M, a DNA vaccine, a viral vaccine, a protein vaccine and an optimized combination of immune methods of the DNA vaccine, the viral vaccine and the protein vaccine in preparation of an anti-tumor vaccine.

Description

technical field [0001] The invention relates to the fields of tumor DNA vaccines, virus vector vaccines and protein vaccines. Specifically, the present invention relates to recombinant DNA vectors CpVR-MS and CpDV-IL2-MS; recombinant protein vaccines S8 and 9M and DNA vaccines, viral vector vaccines, protein vaccines and the optimal combination of immune methods between these three forms of vaccines Use in the preparation of anti-tumor vaccines. Background technique [0002] Survivin is a member of the inhibitor of apoptosis protein (IAP) family, has dual functions of anti-apoptosis and regulation of cell division, and is widely expressed in various embryonic tissues and cancer cells, but not in normal terminally differentiated cells . These characteristics make survivin a new target in the fields of tumorigenesis, development and therapy. [0003] Current research shows that survivin has potential value in tumor gene therapy: its tumor-specific expression is positively c...

AI Technical Summary

Problems solved by technology

From the discovery of MUC1 to the present, a lot of vaccine research work has been carried out with it, and some vaccines have entered the stage of human clinical research, but most of them are traditional polypeptide, protein or dendritic cell (DC) vaccines, Most of these vaccines have problems such as poor immunogenicity or difficulty in preparation; the genetic vaccines that have entered the clinic are mainly recombinant poxvirus vaccines. Although no toxicity has been detected, there are still relatively large safety hazards in primary vaccination-boosting of recombinant poxvirus vaccines directly. , and the clinical effect is not very satisfactory; DNA carrier vaccine is still basically in the preclinical research stage due to its weak immunogenicity

[0007] The previous studies of the inventors of the present invention have shown that increasing the number of VNTRs can enhance the immune effect of MUC1 to a certain extent (see Zhang S et al., 2008). For example, the immune response caused by 33 copies of MUC1 VNTR tandem repeats is significantly stronger than that caused by 2 copies Therefore, the present invention selects 33 tandem repeat sequences MUC1 VNTR as an antigen to design a vaccine, and fuses it with S8 to construct a fusion expression vaccine to enhance the broad-spectrum of vaccine immunity. Spectrum and effectiveness, the combination of survivin and MUC1VNTR for tumor treatment has not been reported

Images